| Cassandra Stevens, | |
|
100 N Academy Ave, Danville, PA 17822-9800 | |
| (570) 271-6377 | |
| Not Available |
| Full Name | Cassandra Stevens |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 3 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881267813 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
As states await the promise of a renewed federal pandemic response and expand the number of Americans who qualify for a shot, some governors are trying to scale up their covid vaccine operations — and smooth out the kinks — with the help of the private sector.
Abraxis BioScience, Inc., a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.
The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bid to accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.
Affymetrix, Inc. today announced that based on preliminary financial data, the Company expects to generate positive operating income and net income on a GAAP basis for the fourth-quarter of 2010. Total revenue for the fourth quarter is expected to be approximately $85 million and includes a $4.8 million milestone payment from a "Powered by Affymetrix" diagnostic partner.
› Verified 9 days ago
| Provider Name | Geisinger Clinic |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
As states await the promise of a renewed federal pandemic response and expand the number of Americans who qualify for a shot, some governors are trying to scale up their covid vaccine operations — and smooth out the kinks — with the help of the private sector.
Abraxis BioScience, Inc., a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.
The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bid to accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.
Affymetrix, Inc. today announced that based on preliminary financial data, the Company expects to generate positive operating income and net income on a GAAP basis for the fourth-quarter of 2010. Total revenue for the fourth quarter is expected to be approximately $85 million and includes a $4.8 million milestone payment from a "Powered by Affymetrix" diagnostic partner.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cassandra Stevens, 39 Brook St, Harveys Lake, PA 18618-2229 Ph: (570) 639-7209 | Cassandra Stevens, 100 N Academy Ave, Danville, PA 17822-9800 Ph: (570) 271-6377 |
News Archive
As states await the promise of a renewed federal pandemic response and expand the number of Americans who qualify for a shot, some governors are trying to scale up their covid vaccine operations — and smooth out the kinks — with the help of the private sector.
Abraxis BioScience, Inc., a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.
BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.
The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bid to accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.
Affymetrix, Inc. today announced that based on preliminary financial data, the Company expects to generate positive operating income and net income on a GAAP basis for the fourth-quarter of 2010. Total revenue for the fourth quarter is expected to be approximately $85 million and includes a $4.8 million milestone payment from a "Powered by Affymetrix" diagnostic partner.
› Verified 9 days ago
Dr. Kylie Connell, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Mr. Dennis V Pirnot, MA Audiologist Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Morgan Justine Barrett, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Amy H Hunter, AUD., CCC-A Audiologist Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6377 | |
Dr. Lindsey Woods, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Ms. Kristen R Pecora, MS Audiologist Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Ms. Virginia A Schenck, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 |